NIH R01 · 2025
PROJECT SUMMARY Background: Prostate cancer (PCa) can develop resistance to androgen receptor (AR)-targeted therapies and progress to AR-indifferent stages, such as NEPC or DNPC, through lineage plasticity. While several driver transcription factors for AR-indifferent PCa have been identified, the mechanisms by which lineage-specific developmental enhancers regain accessibility to those transcription factors remain unclear. FOXA family proteins are pioneer transcription factors that modulate chromatin accessibility by maintaining an accessible nucleosome state. In AR-driven PCa, FOXA1 is overexpressed and defines AR chromatin binding. In AR-independent PCa, FOXA1 expression decreases, while…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.